Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Mollica, Veronica, Di Nunno, Vincenzo, Gatto, Lidia, Santoni, Matteo, Scarpelli, Marina, Cimadamore, Alessia, Lopez-Beltran, Antonio, Cheng, Liang, Battelli, Nicola, Montironi, Rodolfo, Massari, Francesco
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2019
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6627706/
https://ncbi.nlm.nih.gov/pubmed/31207938
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060830
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller